Kelly McGovern

Kelly McGovern

Auto-generated profile, based on publicly available information

Kelly McGovern

Boston Children’s Hospital, Harvard Medical School and HHMI, Boston, MA 02115, USA

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 December 2019 in Science
Verified
Journal Article
Closed access
PDF file
KSKevin O. Saunders
Kevin O. Saunders
KWKevin Wiehe
Kevin Wiehe
MTMing Tian
Ming Tian
PAPriyamvada Acharya
Priyamvada Acharya
TBTodd Bradley
Todd Bradley
BHBarton F. Haynes
Barton F. Haynes
Engineering better bnAbs: A highly effective HIV vaccine has been the goal of vaccinologists for nearly 35 years. A successful vaccine would need to induce broadly neutralizing antibodies (bnAbs) that are capable of neutralizing multiple HIV strains (see the Perspective by Agazio and Torres). Steichen et al. report a strategy in which the first vaccine shot can lead to immune responses that generate desired bnAbs. By combining knowledge of human antibody repertoires and structure to guide design, they validated candidate immunogens through functional preclinical testing. Saunders et al. designed immunogens with differences in binding strength for bnAb precursors, which enabled selection of rare mutations after immunization. The immunogens promoted bnAb precursor maturation in humanized mice and macaques. Science , this issue p. eaax4380 , p. eaay7199 ; see also p. 1197

8 January 2025 in Science Translational Medicine
Verified
Journal Article
Closed access
OSOlivia M. Swanson
Olivia M. Swanson
QZQianyi E. Zhang
Qianyi E. Zhang
EIElizabeth Van Itallie
Elizabeth Van Itallie
MTMing Tian
Ming Tian
ABAlecia R. Brown
Alecia R. Brown
MAMihai L. Azoitei
Mihai L. Azoitei
Elicitation of HIV broadly neutralizing antibodies (bnAbs) by vaccination first requires the activation of diverse precursors, followed by successive boosts that guide these responses to enhanced breadth through the acquisition of somatic mutations. Because HIV bnAbs contain mutations in their B cell receptors (BCRs) that are rarely generated during conventional B cell maturation, HIV vaccine immunogens must robustly engage and expand B cells with BCRs that contain these improbable mutations. Here, we engineered an immunogen that activates diverse precursors of an HIV V3-glycan bnAb and promotes their acquisition of a functionally critical improbable mutation. This immunogen was validated biochemically, structurally, and in three different humanized immunoglobulin mouse models that were designed to test HIV immunogens. These results provide a blueprint for rationally designing priming immunogens that explicitly target the elicitation of antibodies with functional yet improbable mutations.

24 March 2020 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
MTMing Tian
Ming Tian
KMKelly McGovern
Kelly McGovern
HCHwei-Ling Cheng
Hwei-Ling Cheng
PWPeyton Waddicor
Peyton Waddicor
LRLisa Rieble
Lisa Rieble
FAFrederick W. Alt
Frederick W. Alt
Significance: Mouse models can provide fast and cost-effective systems to test HIV-1 vaccine candidates at the preclinical stage. To serve this purpose, mouse models are engineered to express the precursors of human broadly neutralizing antibodies (bnAbs) against diverse HIV-1 strains. Immunization of such mouse models can evaluate the ability of vaccines to mature the precursor antibodies into bnAbs. However, due to the unusual properties of bnAbs, mouse models expressing their precursors often have B cell developmental defects. Herein, we devised and validated a strategy to address this problem. This approach could also facilitate the expression of other clinically relevant antibodies in mature B cells in transgenic mice; immunization of such mice could be used to generate novel antibodies with desirable properties.

3 March 2021 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
MTMing Tian
Ming Tian
HCHwei-Ling Cheng
Hwei-Ling Cheng
MKMichael T. Kimble
Michael T. Kimble
KMKelly McGovern
Kelly McGovern
PWPeyton Waddicor
Peyton Waddicor
FAFrederick W. Alt
Frederick W. Alt
Significance: The immune system can produce enormous varieties of antibodies to counter infections. In this study, we devised a method to harness the power of the immune system to produce therapeutic antibodies. We used this method to generate antibodies against human PD1, a negative regulator of T cell activity. Available anti-PD1 therapeutic antibodies inhibit the function of PD1, thereby boosting T cell activity against tumor cells. We diversified one such anti-PD1 antibody and obtained multiple anti-PD1 antibodies, some of which can stimulate, rather than inhibit, PD1 function in vitro. Such PD1-stimulatory antibodies could potentially be used to suppress pathogenic T cell activities in autoimmune diseases. This method could be used to diversify the functions of other therapeutic antibodies.